UPDATE - UBS Initiates Coverage on HMA (HMA) with a Buy; Initiatives Will Continue to Run
Tweet
Share
E-mailGet Alerts HMA Hot Sheet
Price: $10.54 --0%
Rating Summary:
4 Buy, 15 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
4 Buy, 15 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
UPDATE - UBS initiates coverage on HMA (NYSE: HMA) with a Buy rating. PT $11.
Analyst, A.J. Rice, said, "HMA operates 71 hospitals in 15 states across the southeast U.S. HMA focuses on non-urban markets, and 64% of revenues are derived from Florida, Mississippi and Tennessee. HMA favors Certificate of Need markets where the population is between 50,000 to 500,000, is expanding faster than the national average, and is skewed toward those over age 65."
"Since joining the company in 2008, CEO Gary Newsome has set three initiatives: a) boost Emergency Room operations; b) strengthen physician recruitment; and c) pursue market service development. HMA has also embarked on several cost savings initiatives particularly in the area of orthopaedic, spine and cardiac implants. As a result, HMA is positioned for 8-10% annual EBITDA growth."
To see more ratings on HMA, Click Here
Analyst, A.J. Rice, said, "HMA operates 71 hospitals in 15 states across the southeast U.S. HMA focuses on non-urban markets, and 64% of revenues are derived from Florida, Mississippi and Tennessee. HMA favors Certificate of Need markets where the population is between 50,000 to 500,000, is expanding faster than the national average, and is skewed toward those over age 65."
"Since joining the company in 2008, CEO Gary Newsome has set three initiatives: a) boost Emergency Room operations; b) strengthen physician recruitment; and c) pursue market service development. HMA has also embarked on several cost savings initiatives particularly in the area of orthopaedic, spine and cardiac implants. As a result, HMA is positioned for 8-10% annual EBITDA growth."
To see more ratings on HMA, Click Here
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Starts Faeth Therapeutics (FTH) at Buy
- Keefe, Bruyette & Woods Resumes Canadian Imperial Bank of Commerce (CM:CN) (CM) at Market Perform
- William Blair Starts Tandem Diabetes Care (TNDM) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
